AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

Industry watchers predict AbbVie's Venclexta could hit $2 billion in peak sales. (AbbVie)

AbbVie and Roche’s Venclexta may have recently hit a stumbling block—but in chronic lymphocytic leukemia, it’s rolling.

Wednesday, the FDA approved a combination of the drug and Roche’s Gazyva for previously untreated patients with CLL or small lymphocytic leukemia (SLL). The regimen, approved speedily under the agency’s Real-Time Oncology Review, represents a chemo-free option for patients.

RELATED: Yet another AbbVie-Roche regimen, this time with Venclexta and Gazyva, hits its marks in CLL


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

“Some patients are unable to tolerate chemotherapy regimens due to their underlying health,” Roche’s chief medical officer and head of global product development, Sandra Horning, M.D., said in an October statement after the companies unveiled top-line results.

The approval comes on the back of strong phase 3 data that showed the combo could cut the risk of disease worsening or death by 67% compared with Gazyva plus chlorambucil, a current standard of care. And it’s not the first the partners have collected within the last year; last June, they picked up an FDA approval for a marriage of Venclexta and Roche megablockbuster Rituxan, the predecessor to Gazyva, in previously treated CLL patients.

RELATED: Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients

Both those green lights will help Venclexta toward the $2 billion peak sales mark that analysts have predicted for the drug. But at least for now, multiple myeloma indications won’t. In March, deaths in trials prompted U.S. regulators to halt enrollment of all of Venclexta's myeloma trials; they later revealed that a combination of Venclexta, Takeda proteasome inhibitor Velcade and dexamethasone had doubled patients’ relative risk of death compared with placebo.

Suggested Articles

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

AstraZeneca is still stinging after its SGLT2 drug Farxiga was waved off in Type 1 diabetes, but new heart failure data could ease the pain.